Log in to search using one of your social media accounts:

 

Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia
Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia, Published online: 20 February 2018; doi:10.1038/s41375-018-0059-3Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia (Source: Leukemia)
Source: Leukemia - February 20, 2018 Category: Hematology Authors: Paolo Strati Alessandra Ferrajoli William G. Wierda Nitin Jain Philip A. Thompson Susan M. O ’Brien Katy Rezvani Hagop M. Kantarjian Jan A. Burger Christina O. Hinojosa Michael J. Keating Zeev Estrov Source Type: research

An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignanciesAn “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies, Published online: 20 February 2018; doi:10.1038/s41375-018-0065-5An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies (Source: Leukemia)
Source: Leukemia - February 20, 2018 Category: Hematology Authors: Matthew L Cooper Jaebok Choi Karl Staser Julie K Ritchey Jessica M Devenport Kayla Eckardt Michael P Rettig Bing Wang Linda G Eissenberg Armin Ghobadi Leah N Gehrs Julie L Prior Samuel Achilefu Christopher A Miller Catrina C Fronick Julie O ’Nea Source Type: research

Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria, Published online: 20 February 2018; doi:10.1038/s41375-018-0060-xDepth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria (Source: Leukemia)
Source: Leukemia - February 20, 2018 Category: Hematology Authors: Eli Muchtar Angela Dispenzieri Nelson Leung Martha Q. Lacy Francis K. Buadi David Dingli Martha Grogan Suzanne R. Hayman Prashant Kapoor Yi Lisa Hwa Amie Fonder Miriam Hobbs Rajshekhar Chakraborty Wilson Gonsalves Taxiarchis V. Kourelis Rahma Warsame Step Source Type: research

Mutant IL-7Rα and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemia
Mutant IL-7Rα and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemiaMutant IL-7Rα and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemia, Published online: 15 February 2018; doi:10.1038/s41375-017-0001-0Mutant IL-7Rα and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemia (Source: Leukemia)
Source: Leukemia - February 15, 2018 Category: Hematology Authors: Sarah D. Cramer Julie A. Hixon Caroline Andrews Ross J. Porter Gisele O. A. Rodrigues Xiaolin Wu Tim Back Kelli Czarra Helen Michael Maggie Cam Jack Chen Dominic Esposito Emilee Senkevitch Vijay Negi Peter D. Aplan Wenqing Li Scott K. Durum Source Type: research

Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma
Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma, Published online: 08 February 2018; doi:10.1038/s41375-018-0043-yGenomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma (Source: Leukemia)
Source: Leukemia - February 8, 2018 Category: Hematology Authors: Shamzah Araf Jun Wang Koorosh Korfi Celine Pangault Eleni Kotsiou Ana Rio-Machin Tahrima Rahim James Heward Andrew Clear Sameena Iqbal Jeff K. Davies Peter Johnson Maria Calaminici Silvia Montoto Rebecca Auer Claude Chelala John G. Gribben Trevor Graham T Source Type: research

Whole-exome sequencing reveals acquisition of mutations leading to the onset of donor cell leukemia after hematopoietic transplantation: a model of leukemogenesis
Whole-exome sequencing reveals acquisition of mutations leading to the onset of donor cell leukemia after hematopoietic transplantation: a model of leukemogenesis, Published online: 05 February 2018; doi:10.1038/s41375-018-0042-zWhole-exome sequencing reveals acquisition of mutations leading to the onset of donor cell leukemia after hematopoietic transplantation: a model of leukemogenesis (Source: Leukemia)
Source: Leukemia - February 5, 2018 Category: Hematology Authors: Julia Su árez-González Carolina Mart ínez-Laperche Nerea Mart ínez Gabriela Rodr íguez-Macías Mi Kwon Pascual Balsalobre Diego Carbonell Mar ía Chicano David Serrano Juan Carlos Trivi ño Miguel Ángel Piris Jorge Gayoso Jos é Luis Díez-Martín I Source Type: research

CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+AML and act synergistically with the FLT3-inhibitor crenolanib
CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+AML and act synergistically with the FLT3-inhibitor crenolanibCAR T-cells targeting FLT3 have potent activity against FLT3−ITD+AML and act synergistically with the FLT3-inhibitor crenolanib, Published online: 05 February 2018; doi:10.1038/s41375-018-0009-0CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+AML and act synergistically with the FLT3-inhibitor crenolanib (Source: Leukemia)
Source: Leukemia - February 5, 2018 Category: Hematology Authors: Hardikkumar Jetani Irene Garcia-Cadenas Thomas Nerreter Simone Thomas Julian Rydzek Javier Briones Meijide Halvard Bonig Wolfgang Herr Jordi Sierra Hermann Einsele Michael Hudecek Source Type: research

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts, Published online: 02 February 2018; doi:10.1038/s41375-018-0019-yBlast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts (Source: Leukemia)
Source: Leukemia - February 2, 2018 Category: Hematology Authors: Ayalew Tefferi Mythri Mudireddy Francesco Mannelli Kebede H. Begna Mrinal M. Patnaik Curtis A. Hanson Rhett P. Ketterling Naseema Gangat Meera Yogarajah Valerio De Stefano Francesco Passamonti Vittorio Rosti Maria Chiara Finazzi Alessandro Rambaldi Albert Source Type: research

Utx loss causes myeloid transformation
Utx loss causes myeloid transformation, Published online: 02 February 2018; doi:10.1038/s41375-018-0011-6Utx loss causes myeloid transformation (Source: Leukemia)
Source: Leukemia - February 2, 2018 Category: Hematology Authors: Liting Zheng Longyong Xu Qing Xu Lu Yu Danfeng Zhao Pu Chen Wei Wang Yiqin Wang Gang Han Charlie Degui Chen Source Type: research

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study, Published online: 02 February 2018; doi:10.1038/s41375-018-0023-2Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study (Source: Leukemia)
Source: Leukemia - February 2, 2018 Category: Hematology Authors: S Rule W Jurczak M Jerkeman C Rusconi M Trneny F Offner D Caballero C Joao M Witzens-Harig G Hess I Bence-Bruckler S-G Cho C Thieblemont W Zhou T Henninger J Goldberg J Vermeulen M Dreyling Source Type: research

A human bone marrow mesodermal-derived cell population with hemogenic potential
A human bone marrow mesodermal-derived cell population with hemogenic potential, Published online: 02 February 2018; doi:10.1038/s41375-018-0016-1A human bone marrow mesodermal-derived cell population with hemogenic potential (Source: Leukemia)
Source: Leukemia - February 2, 2018 Category: Hematology Authors: Saloomeh Mokhtari Evan Colletti Weihong Yin Chad Sanada Zanetta Lamar Paul J. Simmons Steven Walker Colin Bishop Anthony Atala Esmail D. Zanjani Christopher D. Porada Gra ça Almeida-Porada Source Type: research

Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients
Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients, Published online: 02 February 2018; doi:10.1038/s41375-018-0018-zRevised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients (Source: Leukemia)
Source: Leukemia - February 2, 2018 Category: Hematology Authors: Ayalew Tefferi Maura Nicolosi Mythri Mudireddy Terra L. Lasho Naseema Gangat Kebede H. Begna Curtis A. Hanson Rhett P. Ketterling Animesh Pardanani Source Type: research

Evolving m-protein pattern in patients with smoldering multiple myeloma: impact on early progression
Evolving m-protein pattern in patients with smoldering multiple myeloma: impact on early progression, Published online: 02 February 2018; doi:10.1038/s41375-018-0013-4Evolving m-protein pattern in patients with smoldering multiple myeloma: impact on early progression (Source: Leukemia)
Source: Leukemia - February 2, 2018 Category: Hematology Authors: Carlos Fern ández de Larrea Ignacio Isola Arturo Pereira Ma Teresa Cibeira Laura Magnano Natalia Tovar Luis-Gerardo Rodr íguez-Lobato Xavier Calvo Juan I. Ar óstegui Tania D íaz Ester Lozano Mar ía Rozman Jordi Yag üe Joan Blad é Laura Rosi ñol Source Type: research

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML, Published online: 30 January 2018; doi:10.1038/leu.2017.348Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML (Source: Leukemia)
Source: Leukemia - January 30, 2018 Category: Hematology Authors: C Sch ütz S Inselmann S Saussele C T Dietz M C M üller E Eigendorff C A Brendel S K Metzelder T H Br ümmendorf C Waller J Dengler M E Goebeler R Herbst G Freunek S Hanzel T Illmer Y Wang T Lange F Finkernagel R Hehlmann M Huber A Neubauer A Hochhaus J Source Type: research

Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia
Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia, Published online: 05 January 2018; doi:10.1038/leu.2017.312Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia (Source: Leukemia)
Source: Leukemia - January 5, 2018 Category: Hematology Authors: S Jo J H Lee J J Mattei D M Barrett P van den Elzen S A Grupp G S D Reid A E Seif Source Type: research

miR-194-5p/BCLAF1 deregulation in AML tumorigenesis
miR-194-5p/BCLAF1 deregulation in AML tumorigenesis, Published online: 22 December 2017; doi:10.1038/leu.2017.310miR-194-5p/BCLAF1 deregulation in AML tumorigenesis (Source: Leukemia)
Source: Leukemia - December 22, 2017 Category: Hematology Authors: C Dell ' Aversana C Giorgio L D ' Amato G Lania F Matarese S Saeed A Di Costanzo V Belsito Petrizzi C Ingenito J H A Martens I Pallavicini S Minucci A Carissimo H G Stunnenberg L Altucci Source Type: research

Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches
Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches, Published online: 19 December 2017; doi:10.1038/leu.2017.333Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches (Source: Leukemia)
Source: Leukemia - December 19, 2017 Category: Hematology Authors: S Pearson A J K Williamson R Blance T C P Somervaille S Taylor N Azadbakht A D Whetton A Pierce Source Type: research

SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia
SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia, Published online: 18 December 2017; doi:10.1038/leu.2017.339SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia (Source: Leukemia)
Source: Leukemia - December 18, 2017 Category: Hematology Authors: J Bu A Chen X Yan F He Y Dong Y Zhou J He D Zhan P Lin Y Hayashi Y Sun Y Zhang Z Xiao H L Grimes Q-f Wang G Huang Source Type: research

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network, Published online: 18 December 2017; doi:10.1038/leu.2017.353Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network (Source: Leukemia)
Source: Leukemia - December 18, 2017 Category: Hematology Authors: H Ludwig M Delforge T Facon H Einsele F Gay P Moreau H Avet-Loiseau M Boccadoro R Hajek M Mohty M Cavo M A Dimopoulos J F San-Miguel E Terpos S Zweegman L Garderet M-V Mateos G Cook X Leleu H Goldschmidt G Jackson M Kaiser K Weisel N W C J van de Donk A W Source Type: research

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells
Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells, Published online: 18 December 2017; doi:10.1038/leu.2017.338Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells (Source: Leukemia)
Source: Leukemia - December 18, 2017 Category: Hematology Authors: B Peter S Bibi G Eisenwort B Wingelhofer D Berger G Stefanzl K Blatt H Herrmann E Hadzijusufovic G Hoermann T Hoffmann J Schwaab M Jawhar M Willmann W R Sperr J Zuber K Sotlar H-P Horny R Moriggl A Reiter M Arock P Valent Source Type: research

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma, Published online: 18 December 2017; doi:10.1038/leu.2017.352Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma (Source: Leukemia)
Source: Leukemia - December 18, 2017 Category: Hematology Authors: A Krishnan P Kapoor J M Palmer N-C Tsai S Kumar S Lonial M Htut C Karanes N Nathwani M Rosenzweig F Sahebi G Somlo L Duarte J F Sanchez D Auclair S J Forman J G Berdeja Source Type: research

Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children’s Oncology Group (COG)
Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children’s Oncology Group (COG)Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children’s Oncology Group (COG), Published online: 18 December 2017; doi:10.1038/leu.2017.341Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children’s Oncology Group (COG) (Source: Leukemia)
Source: Leukemia - December 18, 2017 Category: Hematology Authors: S Gupta M Devidas M L Loh E A Raetz S Chen C Wang P Brown A J Carroll N A Heerema J M Gastier-Foster K P Dunsmore E C Larsen K W Maloney L A Mattano S S Winter N J Winick W L Carroll S P Hunger M Borowitz B L Wood Source Type: research

Chromothripsis in acute myeloid leukemia: Biological features and impact on survival
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival, Published online: 18 December 2017; doi:10.1038/leu.2017.351Chromothripsis in acute myeloid leukemia: Biological features and impact on survival (Source: Leukemia)
Source: Leukemia - December 18, 2017 Category: Hematology Authors: M C Fontana G Marconi J D M Feenstra E Fonzi C Papayannidis A G L di Ror á A Padella V Solli E Franchini E Ottaviani A Ferrari C Baldazzi N Testoni I Iacobucci S Soverini T Haferlach V Guadagnuolo L Semerad M Doubek M Steurer Z Racil S Paolini M Manfrini Source Type: research

AZA-MS: A novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo
AZA-MS: A novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo, Published online: 18 December 2017; doi:10.1038/leu.2017.340AZA-MS: A novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo (Source: Leukemia)
Source: Leukemia - December 18, 2017 Category: Hematology Authors: A Unnikrishnan A V N Quynh R Pickford M J Raftery A C Nunez A Verma L B Hesson J E Pimanda Source Type: research

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia, Published online: 18 December 2017; doi:10.1038/leu.2017.350Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia (Source: Leukemia)
Source: Leukemia - December 18, 2017 Category: Hematology Authors: M Rothenberg-Thurley S Amler D Goerlich T K öhnke N P Konstandin S Schneider M C Sauerland T Herold M Hubmann B Ksienzyk E Zellmeier S K Bohlander M Subklewe A Faldum W Hiddemann J Braess K Spiekermann K H Metzeler Source Type: research

Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells
Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells, Published online: 12 December 2017; doi:10.1038/leu.2017.349Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells (Source: Leukemia)
Source: Leukemia - December 12, 2017 Category: Hematology Authors: P Casado E H Wilkes F Miraki-Moud M M Hadi A Rio-Machin V Rajeeve R Pike S Iqbal S Marfa N Lea S Best J Gribben J Fitzgibbon P R Cutillas Source Type: research

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol
Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol, Published online: 06 December 2017; doi:10.1038/leu.2017.279Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol (Source: Leukemia)
Source: Leukemia - December 6, 2017 Category: Hematology Authors: E M C Driessen P de Lorenzo M Campbell M Felice A Ferster I Hann A Vora L Hovi G Escherich C K Li G Mann T Leblanc F Locatelli A Biondi J Rubnitz M Schrappe L Silverman J Stary R Suppiah T Szczepanski M Valsecchi R Pieters Source Type: research

Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition
Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition, Published online: 06 December 2017; doi:10.1038/leu.2017.158Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition (Source: Leukemia)
Source: Leukemia - December 6, 2017 Category: Hematology Authors: E Leroy S N Constantinescu Source Type: research

The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemiaAG Sanarico et al
The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemiaAG Sanarico et al, Published online: 06 December 2017; doi:10.1038/leu.2017.342The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemiaAG Sanarico et al (Source: Leukemia)
Source: Leukemia - December 6, 2017 Category: Hematology Authors: A G Sanarico C Ronchini A Croce E M Memmi U A Cammarata A De Antoni S Lavorgna M Divona L Giac ò G E M Melloni A Brendolan G Simonetti G Martinelli P Mancuso F Bertolini F L Coco G Melino P G Pelicci F Bernassola Source Type: research

Targeting MYC in multiple myeloma
Targeting MYC in multiple myeloma, Published online: 06 December 2017; doi:10.1038/leu.2017.347Targeting MYC in multiple myeloma (Source: Leukemia)
Source: Leukemia - December 6, 2017 Category: Hematology Authors: K K Jovanovi ć C Roche-Lestienne I M Ghobrial T Facon B Quesnel S Manier Source Type: research

CRISPR/Cas9 edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC
CRISPR/Cas9 edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC, Published online: 06 December 2017; doi:10.1038/leu.2017.346CRISPR/Cas9 edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC (Source: Leukemia)
Source: Leukemia - December 6, 2017 Category: Hematology Authors: I Tirado-Gonzalez E Czlonka A Nevmerzhitskaya D Soetopo E Bergonzani A Mahmoud A Contreras I Jeremias U Platzbecker J P Bourquin U Kloz F Van der Hoeven H Medyouf Source Type: research

Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines
Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines, Published online: 06 December 2017; doi:10.1038/leu.2017.345Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines (Source: Leukemia)
Source: Leukemia - December 6, 2017 Category: Hematology Authors: F Maura M Petljak M Lionetti I Cifola W Liang E Pinatel L Alexandrov A Fullam I Martincorena K J Dawson N Angelopoulos M K Samur R Szalat J Zamora P Tarpey H Davies P Corradini K Anderson S Minvielle A Neri H Avet-Loiseau J J Keats P J Campbell N Munshi N Source Type: research

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups, Published online: 06 December 2017; doi:10.1038/leu.2017.344Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups (Source: Leukemia)
Source: Leukemia - December 6, 2017 Category: Hematology Authors: N Bolli G Biancon M Moarii S Gimondi Y Li C de Philippis F Maura V Sathiaseelan Y-T Tai L Mudie S O ’Meara K Raine J W Teague A P Butler C Carniti M Gerstung T Bagratuni E Kastritis M Dimopoulos P Corradini K Anderson P Moreau S Minvielle P J Campbell E Source Type: research

Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: Documentation and cautionary note regarding cell fraction purity
Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: Documentation and cautionary note regarding cell fraction purity, Published online: 05 December 2017; doi:10.1038/leu.2017.343Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: Documentation and cautionary note regarding cell fraction purity (Source: Leukemia)
Source: Leukemia - December 5, 2017 Category: Hematology Authors: S Marsilio H Khiabanian G Fabbri S Vergani C Scuoppo E Montserrat E J Shpall M Hadigol P Marin K R Rai R Rabadan S Devereux L Pasqualucci N Chiorazzi Source Type: research

MYC-containing amplicons in acute myeloid leukemia: Genomic structures, evolution, and transcriptional consequences
MYC-containing amplicons in acute myeloid leukemia: Genomic structures, evolution, and transcriptional consequences, Published online: 28 November 2017; doi:10.1038/leu.2017.337MYC-containing amplicons in acute myeloid leukemia: Genomic structures, evolution, and transcriptional consequences (Source: Leukemia)
Source: Leukemia - November 28, 2017 Category: Hematology Authors: A ĹAbbate D Tolomeo I Cifola M Severgnini A Turchiano B Augello G Squeo P D ´Addabbo D Traversa G Daniele A Lonoce M Pafundi M Carella O Palumbo A Dolnik D Muehlematter J Schoumans N Van Roy G De Bellis G Martinelli G Merla L Bullinger C Haferlach C T S Source Type: research

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells, Published online: 21 November 2017; doi:10.1038/leu.2017.336 (Source: Leukemia)
Source: Leukemia - November 21, 2017 Category: Hematology Authors: C Botta M Cuc è M R Pitari D Caracciolo A Gull à E Morelli C Riillo L Biamonte M E G Cantafio R Prabhala C Mignogna A Di Vito E Altomare N Amodio M T Di Martino P Correale M Rossi A Giordano N C Munshi P Tagliaferri P Tassone Source Type: research

Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups
Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups, Published online: 21 November 2017; doi:10.1038/leu.2017.311 (Source: Leukemia)
Source: Leukemia - November 21, 2017 Category: Hematology Authors: A Burns R Alsolami J Becq B Stamatopoulos A Timbs D Bruce P Robbe D Vavoulis R Clifford M Cabes H Dreau J Taylor S J L Knight R Mansson D Bentley R Beekman J I Mart ín-Subero E Campo R S Houlston K E Ridout A Schuh Source Type: research

Protein arginine methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in multiple myeloma
Protein arginine methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in multiple myeloma, Published online: 21 November 2017; doi:10.1038/leu.2017.334 (Source: Leukemia)
Source: Leukemia - November 21, 2017 Category: Hematology Authors: A Gull à T Hideshima G Bianchi M Fulciniti M K Samur J Qi Y-T Tai T Harada E Morelli N Amodio R Carrasco P Tagliaferri N C Munshi P Tassone K C Anderson Source Type: research

Towards 'off-the-shelf' genetically modified T-Cells: Prolonging functional engraftment in mice by CD8 veto T-cells
Towards 'off-the-shelf' genetically modified T-Cells: Prolonging functional engraftment in mice by CD8 veto T-cells, Published online: 20 November 2017; doi:10.1038/leu.2017.332 (Source: Leukemia)
Source: Leukemia - November 20, 2017 Category: Hematology Authors: N Or-Geva R Gidron-Budovsky L Radomir Y Edelstein A K Singh R Sidlik-Muskatel E Ophir E Bachar-Lustig Y Reisner Source Type: research

Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T cell model system
Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T cell model system, Published online: 20 November 2017; doi:10.1038/leu.2017.328 (Source: Leukemia)
Source: Leukemia - November 20, 2017 Category: Hematology Authors: S Bornschein S Demeyer R Stirparo O Gielen C Vicente E Geerdens B Ghesqui ère S Aerts J Cools C E de Bock Source Type: research

Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used
Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used, Published online: 20 November 2017; doi:10.1038/leu.2017.335 (Source: Leukemia)
Source: Leukemia - November 20, 2017 Category: Hematology Authors: X Bossuyt M Delforge M Reynders D Dillaerts B Sprangers K Fostier K Poesen M Vercammen Source Type: research

Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients
Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients, Published online: 17 November 2017; doi:10.1038/leu.2017.315 (Source: Leukemia)
Source: Leukemia - November 17, 2017 Category: Hematology Authors: T K Bera Y Abe T Ise A Oberle D Gallardo X-f Liu S Nagata M Binder I Pastan Source Type: research

Management of relapsed & refractory multiple myeloma—novel agents, antibodies, immunotherapies and beyond
Management of relapsed & refractory multiple myeloma—novel agents, antibodies, immunotherapies and beyondManagement of relapsed & refractory multiple myeloma—novel agents, antibodies, immunotherapies and beyond, Published online: 16 November 2017; doi:10.1038/leu.2017.329 (Source: Leukemia)
Source: Leukemia - November 16, 2017 Category: Hematology Authors: C S Chim S Kumar R Orlowski G Cook P G Richardson M Gertz S Giralt M Mateos X Leleu K C Anderson Source Type: research

Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time
Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time, Published online: 16 November 2017; doi:10.1038/leu.2017.331 (Source: Leukemia)
Source: Leukemia - November 16, 2017 Category: Hematology Authors: S K Kumar A Dispenzieri R Fraser F Mingwei G Akpek R Cornell M Kharfan-Dabaja C Freytes S Hashmi G Hildebrandt L Holmberg R Kyle H Lazarus C Lee J Mikhael T Nishihori J Tay S Usmani D Vesole R Vij B Wirk A Krishnan C Gasparetto T Mark Y Nieto P Hari A D Source Type: research

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma, Published online: 16 November 2017; doi:10.1038/leu.2017.327 (Source: Leukemia)
Source: Leukemia - November 16, 2017 Category: Hematology Authors: S Bringhen M D ’Agostino L De Paoli V Montefusco A M Liberati P Galieni S Grammatico V E Muccio F Esma C De Angelis P Musto S Ballanti M Offidani R M T Petrucci G Gaidano P Corradini A Palumbo P Sonneveld M Boccadoro Source Type: research

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis, Published online: 16 November 2017; doi:10.1038/leu.2017.330 (Source: Leukemia)
Source: Leukemia - November 16, 2017 Category: Hematology Authors: A Pardanani J Gotlib A W Roberts M Wadleigh S Sirhan J Kawashima J A Maltzman L Shao V Gupta A Tefferi Source Type: research

Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS
Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS, Published online: 16 November 2017; doi:10.1038/leu.2017.326 (Source: Leukemia)
Source: Leukemia - November 16, 2017 Category: Hematology Authors: Y Mei B Zhao A A Basiorka J Yang L Cao J Zhang A List P Ji Source Type: research

Genotoxic stresses promote clonal expansion of hematopoietic stem cells expressing mutant p53
Genotoxic stresses promote clonal expansion of hematopoietic stem cells expressing mutant p53, Published online: 16 November 2017; doi:10.1038/leu.2017.325 (Source: Leukemia)
Source: Leukemia - November 16, 2017 Category: Hematology Authors: S Chen R Gao C Yao M Kobayashi S Z Liu M C Yoder H Broxmeyer R Kapur H S Boswell L D Mayo Y Liu Source Type: research

Gene dosage reductions of Trf1 and/or Tin2 induce telomere DNA damage and lymphoma formation in aging mice
Gene dosage reductions of Trf1 and/or Tin2 induce telomere DNA damage and lymphoma formation in aging mice, Published online: 10 November 2017; doi:10.1038/leu.2017.224 (Source: Leukemia)
Source: Leukemia - November 10, 2017 Category: Hematology Authors: K Hartmann A Illing F Leith äuser A Baisantry L Quintanilla-Martinez K L Rudolph Source Type: research

Bruton's Tyrosine Kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia
Bruton's Tyrosine Kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia, Published online: 07 November 2017; doi:10.1038/leu.2017.324 (Source: Leukemia)
Source: Leukemia - November 7, 2017 Category: Hematology Authors: S C Nimmagadda S Frey B Edelmann C Hellmich L Zaitseva G M K önig E Kostenis K M Bowles T Fischer Source Type: research